Diffuse Alveolar Hemorrhage without Extrapulmonary Manifestations: A Rare Presentation of Lupus

Bharat Bajantri, Binita Sapkota, Sindhaghatta Venkatram

Corresponding Author: Bharat Bajantri, e-mail: bharatbajantri@gmail.com

Conflict of interest: None declared

Patient: Female, 31
Final Diagnosis: Lupus DAH
Symptoms: Shortness of breath
Medication: —
Clinical Procedure: —
Specialty: Pulmonology

Objective: Unusual clinical course

Background: Diffuse alveolar hemorrhage (DAH) is a life-threatening disorder resulting in hemorrhage into the lungs due to a variety of reasons. The underlying etiology for DAH is broadly divided into immune and non-immune mediated causes. Rheumatological disorders account for a small number of cases. Although hemoptysis is one of the alarming symptoms of DAH, it is absent in a third of the cases. Diagnosis often requires a conglomerate of history, clinical, and laboratory investigation and radiological studies.

Case Report: We describe a case of a 31-year-old female who had an atypical presentation of systemic lupus erythematosus (SLE) with primary lung involvement/DAH and no other organ involvement.

Conclusions: This case report illustrates the importance of awareness and early recognition of the complication that can prevent mortality.

MeSH Keywords: Bronchoalveolar Lavage Fluid • Hemorrhage • Lupus Erythematosus, Systemic

Full-text PDF: https://www.amjcaserep.com/abstract/index/idArt/907148
Background

Diffuse alveolar hemorrhage (DAH) is a life-threatening condition which refers to hemorrhage originating from pulmonary microvasculature. This a clinicopathological syndrome resulting in alveolar filling of the blood. Pulmonary capillaritis is the most frequent histopathological pattern described. It can be associated with any condition that leads to inflammatory changes causing capillaritis [1]. Most common causes of pulmonary capillaritis are due to rheumatological disorders. DAH as a manifestation of systemic lupus erythematosus (SLE) occurs in 1% to 5% of SLE cases [1–3]. Extrapulmonary signs and symptoms of SLE frequently accompany DAH, with nephritis as the most common manifestation. SLE presenting as DAH without any other manifestations is very rare. We report a case of a young female patient without any prior history, who presented with bilateral infiltrates and bronchoscopy revealed DAH; investigations for DAH revealed SLE.

Case Report

A 31-year-old female presented to our emergency department (ED) with a one-week history of cough and shortness of breath. Her cough was productive with yellow sputum that was blood tinged only on a couple of occasions. She denied any fever, chills, night sweats, headache, runny nose, or sore throat. Shortness of breath was exertional, and her exercise tolerance had decreased from 10 blocks to few steps in the last week. The patient was also having normal menses without any excessive bleeding. She also admitted to having lost 15 pounds in one week associated with poor appetite. Her medical history included hypertension, which was well controlled. There was no significant family history. She denied using tobacco or any illicit drugs but admitted to drinking alcohol occasionally. She had no known allergies. Her only home medication was amlodipine. Her surgical history was significant for tonsillectomy. She has had two uncomplicated pregnancies resulting in two healthy children. She was hemodynamically stable on arrival to the ED with vitals: blood pressure was 157/100 mm Hg, heart rate 91 beats per minute, respiratory rate of 16 breaths per minute, temperature 36.7°C, and oxygen saturation 99% on room air. Physical examination revealed bilateral basal crepitations and loud P2 on auscultation of lungs and heart, respectively. The rest of the examination was unremarkable. Her laboratory investigations are summarized in Tables 1 and 2. The images of her chest x-ray are shown in Figure 1.

She was started on antibiotics for suspected community acquired pneumonia. She developed hypoxia needing supplemental oxygen. A CT chest was performed, and the images are shown in Figure 2.

She underwent diagnostic bronchoscopy in the operating room under general anesthesia and her bronchoalveolar lavage (BAL) was consistent with DAH as shown in Figure 3.

Post procedure she needed ventilatory support. She was started on intravenous Solu-Medrol 1,000 mg daily. Autoimmune workup was consistent with the diagnosis of SLE. After five

Table 1. Laboratory values.

| Parameters (units) (normal values) | Day 1 (on admission) | Day 2 | Day 4 |
|-----------------------------------|----------------------|------|------|
| Hemoglobin (g/dL) (12.0–16.0)     | 7.7                  | 8.1  | 7.9  |
| Hematocrit (%) (42%–51%)          | 24.5                 | 25   | 25   |
| White cell count (k/uL) (4.8–10.8) | 2.5                  | 3.0  | 4.1  |
| Platelet (k/uL) (150–400)         | 166                  | 158  | 148  |
| Prothrombin time (9.5–12.0)       | 12                   |      |      |
| Partial thromboplastin time (26.1–33.8) | 25.3               |      |      |
| Serum sodium (mEq/L) (135–145)    | 139                  | 138  | 137  |
| Serum potassium (mEq/L) (3.5–5.0) | 3.8                  | 4.1  | 3.9  |
| Serum bicarbonate (mEq/L) (24–30) | 19                   | 17   | 18   |
| Serum blood urea nitrogen (mg/dL) (6–20) | 11               | 6    | 7    |
| Serum creatinine (mg/dL) (0.5–1.5) | 0.8                 | 0.7  | 0.7  |
| Urine toxicology                  | Cannabinoids         |      |      |
| Serum creatinine kinase (unit/L) (mg/dL) | 52             |      |      |
| Serum human chorionic gonadotropin (mIU/mL) | 0.3         |      |      |
Table 2. Autoimmune workup.

| Autoimmune workup                      | Results          |
|----------------------------------------|------------------|
| Myeloperoxidase antibodies             | Undetectable     |
| Proteinase-3 antibodies                | Undetectable     |
| Antiscleroderma-70 antibody            | Negative         |
| Antinuclear antibody                   | Positive         |
| Antinuclear antibody pattern           | Speckled         |
| Antinuclear antibody titers            | 1: 320           |
| Anti-deoxyribonucleic acid antibody (IU/mL) | >300          |
| Rheumatoid factor (IU/mL)              | <14              |
| Serum C3 complement (mg/dL)            | 17               |
| Serum C4 complement (mg/dL)            | 5                |
| Anti-Smith antibody                    | >8               |
| Anti-ribonucleoprotein antibody         | >8               |
| Lupus anticoagulant                    | Negative         |
| Anti-cardiolipin antibodies            | Negative         |

Figure 1. Chest x-ray showing bilateral lower lobe infiltrates.

Figure 2. Computed tomography of the chest showing diffuse bilateral interstitial pattern with areas of more confluent ground glass density in the lower lobes.

Figure 3. Sequential bronchoalveolar lavage (BAL) consistent with diffuse alveolar hemorrhage.
days of intravenous Solu-Medrol, she was switched to tapering doses of oral steroids and mycophenolate was started. She responded to therapy and was successfully extubated. She symptomatically improved and was discharged. She was followed in pulmonary and rheumatology clinics post discharge without any recurrence in symptoms and is doing well.

**Discussion**

DAH is a devastating clinical syndrome characterized by a falling hematocrit, respiratory insufficiency, and radiographic evidence of pulmonary infiltrates. Pulmonary capillaritis is the instigating agent in a majority of cases. Common diseases resulting in DAH include granulomatosis with polyangiitis, Goodpasture syndrome, Idiopathic pulmonary hemosiderosis, collagen vascular diseases, and microscopic polyangiitis. DAH is a rare manifestation in SLE seen in 4% of patients with SLE admitted to the hospital. DAH, as a presenting manifestation of childhood SLE, was reported in 29% of cases in one study [4]. In most case series of DAH in lupus, the diagnosis of SLE was established, although in 10% to 20% of cases, DAH was a presenting manifestation, all of these patients had extrapulmonary manifestations [2,5].

**Pathogenesis**

The three histologic patterns recognized in alveolar hemorrhage are: pulmonary capillaritis, bland pulmonary hemorrhage, and diffuse alveolar damage. Pulmonary capillaritis is the most frequent pattern described. The underlying etiology is broadly divided into immune and non-immune mediated causes [6]. Occasionally, recurrent episodes of DAH with no apparent etiology are seen, called idiopathic hemosiderosis. Two types of DAH are seen in SLE: “bland alveolar hemorrhage” i.e., capillaritis without any evidence of vasculitis, and capillaritis with vasculitis. Although the former is thought to be more common, the latter is seen in 80% of cases at autopsy. Immune complex deposits can be seen in both types of DAH and appear to be similar to lupus manifestations of the kidney [1].

**Clinical features**

The clinical manifestations of DAH are rather vague respiratory symptoms including that of cough and dyspnea. Although hemoptysis is one of the alarming symptoms of DAH, it is absent in a third of the cases with DAH; hence, high index of suspicion is paramount in patients with DAH [6,7]. Anemia or a drop of hematocrit level with no obviously bleeding source, along with low serum C3 complement levels and hypoxia are independent predictors of DAH in SLE [6,8]. A study by Kazzaz et al. showed many factors that predicted DAH in SLE patients including thrombocytopenia, cardiac valve disease, low C3 complement, leucopenia, neuropsychiatric features, hemolysis, arterial thrombosis, lupus anticoagulant, secondary APS, and low C4 complement by univariate analysis; however, multivariate analysis was significant for thrombocytopenia and low serum C3 complement levels [9]. Poor prognostic markers for DAH include renal failure, thrombocytopenia, concomitant infection, neuro-psychiatric illness, use of cyclophosphamide, and requirement of mechanical ventilation [2,10–12]. Other predictors of DAH include Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [12,13].

**Chest imaging**

Chest imaging, x-ray, and high resolution computed tomographic (HRCT) features are non-specific showing opacities that cannot be differentiated from other consolidative processes; however, the presence of pleural effusion eliminates the diagnosis of DAH. Evolution of opacities for the worse or the better is rapid and is notable in 48 hours [1]. The resolution of radiographic infiltrates is faster than seen in pneumonia, and slower than that of pulmonary edema [6].

**Diagnosis**

Diagnosis of DAH requires fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) with evidence of increasingly hemorrhagic return of bronchial washings from sequential BAL. Although not very specific, a clue for recent alveolar hemorrhage is intact erythrocytes in macrophages as opposed to hemosiderin laden macrophages in occult or chronic hemorrhages [14]. Histological diagnosis of DAH is evidenced by Golde score. It is the count of Prussian blue-stained macrophages graded from 1 to 4 based on the intensity of the stain among 100 cells under the microscope. Scores more than 100 are indicative of DAH. Scores more than 100 often correlated with siderophage of 67% [1]. Siderophages of more than 20% in BAL also have been shown to be strongly associated with DAH [1,6]. On the contrary, siderophage by itself has a less than optimum specificity for DAH as it can be seen in patients with congestive heart failure with chronic pulmonary edema. BAL must be further investigated for infectious and non-infectious causes, including cytological etiologies for DAH [1,6].

Lung biopsies, although considered gold standard for connective tissue disease (CTD) induced DAH, have become obsolete with the emergence of pertinent serological antibodies and prevalent radiological abnormalities. Moreover, invasive procedures for biopsy specimens do not alter the line of management and on the contrary, are associated with substantial risk of bleeding [1,6,15].

**Pulmonary function tests**

Isolated decreased DLCO (diffusion capacity of carbon monoxide) was found to be the most frequent abnormality followed
Management

DAH is an autoimmune disease emergency and therapy should be initiated as soon as diagnosis is suspected or established. Intravenous methylprednisolone doses as high as 500 mg every six hours for four to five days followed by tapering doses to oral steroids have shown to be efficacious [18]. Off-label use of recombinant factor VIIa in refractory cases of DAH, immune and non-immune mediated, can be considered as has been shown in case reports and case series. It can be administered intravenously or bronchoscopically for endobronchial instillation [19–23]. Plasma exchange therapy is reserved for patients with refractory hypoxic respiratory failure requiring ventilator support and has been endorsed by the American Society of Apheresis, and is recommended to be performed daily or on alternate days for at least two weeks. Long term benefits remain skeptical [24].

In intubated patients, supportive ventilatory care is followed. Lung protective ventilation is employed in patients presenting as ARDS. Extracorporeal membrane oxygenation (ECMO) has been reported to be used with survival benefit in patients with SLE-related DAH, [25,26].

Other immunosuppressants that have been reported to be used in CTD-related DAH with a trend towards optimal responses are: cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab, methotrexate, etanercept, and imatinib [6,27–31]. Advanced treatments like umbilical cord-derived mesenchymal stem cell transplantation have come to light in the recent past, but more evidence is need before it can become the standard of care [32,33].

Conclusions

DAH is a catastrophic illness that is life threatening with a high mortality rate. In patients presenting with DAH without any extrapulmonary manifestations, workup should include a collagen vascular profile. DAH is associated with SLE, and it seems to be rather under reported, secondary to lack of recognition as well as its rare occurrence. Awareness of this association irrespective of other more common extrapulmonary manifestation is of utmost importance not only because of its association with high rates of mortality but also because appropriate early interventions can drastically reduce mortality.

Conflict of interest

None.

References:

1. Cordier JF, Cottin V: Alveolar hemorrhage in vasculitis. Primary and secondary. Semin Respir Crit Care Med, 2011; 32(3): 310–21
2. Zamora MR, Warner ML, Tuder R, Schwarz MI: Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore), 1997; 76(3): 192–202
3. Carette S, Macher AM, Nussbaum A, Plotz PH: Severe, acute pulmonary disease in patients with systemic lupus erythematosus. Ten years of experience at the National Institutes of Health. Semin Arthritis Rheum, 1984; 14(1): 52–59
4. Singla S, Canter DL, Vece TJ et al: Diffuse alveolar hemorrhage as a manifestation of childhood-onset systemic lupus erythematosus. Hosp Pediatr, 2016; 6(8): 496–500
5. Andrade C, Mendonca T, Farinha F et al: Alveolar hemorrhage in systemic lupus erythematosus: A cohort review. Lupus, 2016; 25(1): 75–80
6. Krause ML, Cartin-Ceba R, Specks U, Peikert T: Update on diffuse alveolar hemorrhage and pulmonary vasculitis. Immunol Allergy Clin North Am, 2012; 32(4): 587–600
7. Casian A, Jayne D: Management of alveolar hemorrhage in lung vasculitides. Semin Respir Crit Care Med, 2011; 32(3): 335–45
8. Kim D, Choi I, Cho SK et al: Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. Semin Arthritis Rheum, 2017; 46(6): 782–87
9. Kazzaz NM, Coit P, Lewis EE et al: Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: Risk factors, therapy and survival. Lupus Sci Med, 2015; 2(1): e000117
10. Mittoo S, Fell CD: Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med, 2014; 35(2): 249–54
11. Ednalino C, Yip J, Carsons SE: Systematic review of diffuse alveolar hemorrhage in systemic lupus erythematosus: Focus on outcome and therapy. J Clin Rheumatol, 2015; 21(6): 305–10
12. Kwok SK, Moon SJ, Ju JH et al: Diffuse alveolar hemorrhage in systemic lupus erythematosus: Risk factors and clinical outcome: Results from affiliated hospitals of Catholic University of Korea. Lupus, 2011; 20(3): 102–7
13. Badiha H, Teh CI, Kong KO et al: Pulmonary hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum, 2004; 33(6): 414–21
14. Fishbein GA, Fishbein MC: Lung vasculitis and alveolar hemorrhage. Pathology. Semin Respir Crit Care Med, 2011; 32(3): 254–63
15. Usriam A, Jones KD: Pulmonary pathology in connective tissue disease. Semin Respir Crit Care Med, 2014; 35(2): 201–12
16. Andonopoulos AP, Constantopoulos SH, Galanopoulou V et al: Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest, 1988; 94(2): 312–15
17. Silberstein SL, Barland P, Grayzel AI, Koerner SK: Pulmonary dysfunction in systemic lupus erythematosus: Prevalence classification and correlation with other organ involvement. J Rheumatol, 1980; 7(2): 187–95
18. Ioachimescu OC, Stoller JK: Diffuse alveolar hemorrhage: Diagnosing it and finding the cause. Cleve Clin J Med, 2008; 75(4): 258, 60, 64–65 passim
19. Henke D, Falk RJ, Gabriel DA: Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med, 2004; 140(6): 493–94
20. Heslet L, Nielsen JD, Levi M et al: Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Crit Care, 2006; 10(6): R177
21. Hicks K, Peng D, Gajewski JL: Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant, 2002; 30(12): 975–78

22. Pastores SM, Papadopoulos E, Voigt L, Halpern NA: Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: Treatment with recombinant factor VIIa. Chest, 2003; 124(6): 2400–3

23. Pathak V, Kuhn J, Gabriel D et al: Use of activated Factor VII in patients with diffuse alveolar hemorrhage: a 10 years institutional experience. Lung, 2015; 193(3): 375–79

24. Szczepiorkowski ZM, Winters JL, Bandarenko N et al: Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher, 2010; 25(3): 83–177

25. Patel JJ, Lipchik RI: Systemic lupus-induced diffuse alveolar hemorrhage treated with extracorporeal membrane oxygenation: A case report and review of the literature. J Intensive Care Med, 2014; 29(2): 104–9

26. Pacheco Claudio C, Charbonney E, Durand M et al: Extracorporeal membrane oxygenation in diffuse alveolar hemorrhage secondary to systemic lupus erythematosus. J Clin Med Res, 2014; 6(2): 145–48

27. Maher TM: Immunosuppression for connective tissue disease-related pulmonary disease. Semin Respir Crit Care Med, 2014; 35(2): 265–73

28. Yates M, Watts RA, Bajema IM et al: EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis, 2016; 75(9): 1583–94

29. Scheiman Elazary A, Klahr PP, Hershko AV et al: Rituximab induces resolution of recurrent diffuse alveolar hemorrhage in a patient with primary antiphospholipid antibody syndrome. Lupus, 2012; 21(4): 438–40

30. Erickson RW, Franklin WA, Emlen W: Treatment of hemorrhagic lupus pneumonia with plasmapheresis. Semin Arthritis Rheum, 1994; 24(2): 114–23

31. Pottier V, Pierrot M, Subra IF et al: Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage. Lupus, 2011; 20(6): 656–59

32. Shi D, Wang D, Li X et al: Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus. Clin Rheumatol, 2012; 31(5): 841–46

33. Liang J, Gu F, Wang H et al: Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE. Nat Rev Rheumatol, 2010; 6(8): 486–89